Product Description
For advanced solid tumors (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04713891)
Mechanisms of Action: EP4 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Keythera Pharmaceuticals (Australia)
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, China
Active Clinical Trial Count: 2
Highest Development Phases
Phase 1: Bladder Cancer|Colorectal Cancer|Esophageal Cancer|Gastrointestinal Cancer|Lung Cancer|Oncology Solid Tumor Unspecified|Squamous Cell Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
KFCS001 | P1 |
Completed |
Esophageal Cancer|Colorectal Cancer|Gastrointestinal Cancer|Lung Cancer|Bladder Cancer|Squamous Cell Carcinoma |
2022-12-08 |
|
CTR20211433 | P1 |
Not yet recruiting |
Oncology Solid Tumor Unspecified |
None |